# EDGAR Filing Document

**Accession Number:** 0000896264
**File Stem:** 0000896264-25-000213
**Filing Date:** 2025-10
**Character Count:** 72005
**Document Hash:** 87ffea2c75ace86c9b18a5354d49880e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000896264-25-000213.hdr.sgml**: 20251022

**ACCESSION NUMBER**: 0000896264-25-000213

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20251022

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251022

**DATE AS OF CHANGE**: 20251022

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** USANA HEALTH SCIENCES INC
- **CENTRAL INDEX KEY:** 0000896264
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870500306
- **STATE OF INCORPORATION:** UT
- **FISCAL YEAR END:** 1228

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35024
- **FILM NUMBER:** 251410262

**BUSINESS ADDRESS:**
- **STREET 1:** 3838 WEST PARKWAY BLVD.
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84120-6336
- **BUSINESS PHONE:** 8019547100

**MAIL ADDRESS:**
- **STREET 1:** 3838 WEST PARKWAY BLVD.
- **STREET 2:** 3838 WEST PARKWAY BLVD.
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84120-6336

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USANA INC
- **DATE OF NAME CHANGE:** 19930125

?xml version='1.0' encoding='ASCII'? usna-20251022

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**_____________________**

**FORM 8-K**

**_____________________**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

October 22, 2025

**USANA HEALTH SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

Utah

(State or other jurisdiction of incorporation)

001-35024 87-0500306 <br> (Commission File No.) (IRS EmployerIdentification No.)

3838 West Parkway Boulevard

Salt Lake City**,** Utah 84120

(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value per share | USNA | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On October 22, 2025, USANA Health Sciences, Inc. (the "Company" or "USANA") issued a press release announcing its financial results for the third quarter ended September 27, 2025. The release also announced that the Company will post a document titled "Management Commentary" on the Company's website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company's management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. These documents will be posted on the Company's corporate website, www.usana.com.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

**Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure**

The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press release issued by USANA Health Sciences, Inc. dated October 2](ex991earningsreleaseq32025.htm)[2](ex991earningsreleaseq32025.htm)[, 2025 (furnished herewith).](ex991earningsreleaseq32025.htm)</u> |
| 99.2 | <u>[Management Commentary provided by USANA Health Sciences, Inc. dated October 2](ex992managementcommentaryq.htm)[2](ex992managementcommentaryq.htm)[, 2025 (furnished herewith).](ex992managementcommentaryq.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **USANA HEALTH SCIENCES, INC.** | **USANA HEALTH SCIENCES, INC.** |
| | **By:** | /s/ G. Douglas Hekking |
| | G. Douglas Hekking, Chief Financial Officer | G. Douglas Hekking, Chief Financial Officer |
| Date: October 22, 2025 |  |  |

---

## Exhibit 99.1

![usanacorplogoresized.jpg](usanacorplogoresized.jpg)

**USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook**

**SALT LAKE CITY, October 22, 2025** (BUSINESS WIRE)—USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 27, 2025.

**Key Financial Results**

***Third Quarter 2025 vs. Third Quarter 2024***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales of $214 million versus $200 million, representing 7% year-over-year growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss of -$6.5 million versus net earnings of $10.6 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Diluted EPS of -$0.36 as compared with $0.56.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted diluted EPS<sup>(1)</sup> of -$0.15 as compared with $0.56.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA<sup>(2)</sup> of $13.8 million versus $24.6 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Direct selling Active Customers of 388,000 versus 452,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hiya Active Monthly Subscribers of 193,400.

**Q3 2025 Financial Performance**

---

| | | | |
|:---|:---|:---|:---|
| **Consolidated Results** | **Consolidated Results** | **Consolidated Results** | **Consolidated Results** |
| | | **Year-Over-Year** | **Sequentially** |
| **Net Sales** | $214 million | +7% (No meaningful FX impact) | -9% |
| **Net (Loss) Earnings\*** | -$6.5 million | N/A | N/A |
| **Diluted EPS** | -$0.36 | N/A | N/A |
| **Adjusted Diluted EPS**<sup>(1)</sup> | -$0.15 | N/A | N/A |
| **Adjusted EBITDA**<sup>(2)</sup> | $13.8 million | -44% | -55% |

---

*\*Pretax earnings for Q3 2025 totaled $1.8 million with income tax expense of $8.5 million. The adjustment to income taxes during the period, as a result of updating the annual effective tax rate, is about $7.6 million greater than what would have been expected using the previously guided 45% tax rate.*

*Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.*

------

"USANA provided third quarter results in line with the preliminary results we announced on October 9, 2025," said Jim Brown, President and Chief Executive Officer. "We rolled out our enhanced Brand Partner compensation plan during the third quarter. Since this launch, our commercial team has been actively training, educating and supporting Brand Partners across our global markets to help them leverage the new plan. We are encouraged by the pickup in sales activity and leader productivity in recent weeks. Our enhanced compensation plan represents a bold and strategic move to modernize our business and better position our Brand Partners, and the Company, for long-term success in a competitive landscape.

"We held a successful Global Convention in Salt Lake City during the third quarter where we launched several new and upgraded products, recognized our Brand Partners, and trained them on our enhanced compensation plan. Our commercial team will continue to work alongside our Brand Partners over the next several quarters to help promote our new products and compensation plan. We remain confident that our product and opportunity strategy will position the Company to drive growth in our direct selling business and deliver long-term value for our stakeholders.

"Hiya, our direct-to-consumer (DTC) business, has delivered 26% year-to-date sales growth, and made significant progress on several integration initiatives during the quarter, including the transition to a new logistics partner, which is anticipated to drive operational efficiency. We are also leveraging USANA's manufacturing expertise to support Hiya and will begin bringing their products in-house over the next several months. We continue to expect Hiya to generate double-digit sales growth for 2025 and remain confident in their long-term growth."

**Q3 2025 Direct Selling Regional Results:**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** |
| | | **Year-Over-Year** | **Year-Over-Year (Constant Currency)** | **Sequentially** |
| **Net Sales** | $140 million | -13% | -13% | -15% |
| **Active Customers** | 308000 | -14% | N/A | -8% |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** |
| | | | **Year-Over-Year** | **Year-Over-Year (Constant Currency)** | **Sequentially** |
| **Greater China** | **Net Sales** | $93 million | -9% | No meaningful FX impact | -18% |
| **Greater China** | **Active** | 210000 | -14% | N/A | -9% |
| **Greater China** | **Customers** | 210000 | -14% | N/A | -9% |
| **North Asia** | **Net Sales** | $18 million | -14% | -12% | +3% |
| **North Asia** | **Active** | 37000 | -10% | N/A | —% |
| **North Asia** | **Customers** | 37000 | -10% | N/A | —% |
| **Southeast Asia Pacific** | **Net Sales** | $29 million | -22% | -23% | -11% |
| **Southeast Asia Pacific** | **Active** | 61000 | -20% | N/A | -10% |
| **Southeast Asia Pacific** | **Customers** | 61000 | -20% | N/A | -10% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** |
| | | **Year-Over-Year** | **Year-Over-Year (Constant Currency)** | **Sequentially** |
| **Net Sales\*** | $43 million | +8% | +8% | +12% |
| **Active Customers** | 80000 | -13% | N/A | -2% |

---

*\*Includes $7 million of 'Other'*

**Q3 2025 Hiya Direct to Consumer Results:**

---

| | |
|:---|:---|
| **Hiya** | **Hiya** |
| **Net Sales** | $31 million |
| **Active Monthly Subscribers** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;193400 |

---

**Balance Sheet**

The Company ended the quarter with $145 million in cash and cash equivalents and no debt. The Company has approximately $34 million remaining under the current share repurchase authorization as of the end of the third quarter.

**Fiscal Year 2025 Outlook**

The Company is updating its outlook for fiscal year 2025, as follows:

------

---

| | | |
|:---|:---|:---|
| **Fiscal Year 2025 Outlook** | **Fiscal Year 2025 Outlook** | **Fiscal Year 2025 Outlook** |
| | **Updated Estimate** | **Previous Range** |
| **Consolidated net sales** | $920 million | $920 million to $1.0 billion |
| **Net earnings** | $15 million | $29 million to $41 million |
| **Diluted EPS** | $0.78 | $1.50 to $2.20 |
| **Adjusted Diluted EPS**<sup>(1)</sup> | $1.73 | $2.35 to $3.00 |
| **Adjusted EBITDA**<sup>(2)</sup> | $98 million | $107 million to $123 million |

---

*Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.*

Doug Hekking, Chief Financial Officer, commented, "Short-term profitability was burdened during the third quarter due to softer than anticipated sales, meaningful investments to support the roll out of our enhanced Brand Partner compensation plan, and a change in the estimated annual effective income tax rate that disproportionately impacted the current year quarter. Specifically, lower than expected earnings coupled with the concentration of operating and administrative expenses in the United States resulted in a meaningful increase in the annualized effective income tax rate in the third quarter from 45% to 65%. The adjustment was approximately $7.6 million greater than what would have been expected using the previously guided 45% tax rate.

"Our revised outlook reflects modest sequential improvement in both our direct sales and DTC businesses, albeit from a lower customer base as a result of third quarter performance. We have initiated and are executing a comprehensive process to align all costs throughout the business globally with our current level of sales. As a result of this realignment and rightsizing process, we expect to incur an estimated one-time charge of $4.7 million in the fourth quarter, which is reflected in our updated outlook. We will provide an update on this process, including the actual charge, when we report our fourth quarter and full-year results early next year."

The Company's fiscal 2025 outlook reflects:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales from the direct selling business of approximately $788 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales from Hiya of approximately $132 million, reflecting year-over-year growth of 16%;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Fiscal 2025 is a 53-week year and includes one additional week of sales compared to fiscal 2024. Prior to 2025, the last 53-week year was in fiscal 2020.

------

_________________________

(1) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted Earnings Per Share. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

(2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

**Non-GAAP Financial Measures** 

This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, and transaction-related expenses and integration costs for the Hiya acquisition. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.

------

Adjusted diluted earnings per share (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, and integration costs related to the Hiya acquisition.

Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted earnings per share (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP") and investors should not directly compare with or infer relationship from any of the Company's operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted earnings per share. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.

------

**Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP)**

**(in thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Nine months ended** | **Nine months ended** |
| | **September 27, 2025** | **September 28, 2024** | **September 27, 2025** | **September 28, 2024** |
| **Net earnings (loss) attributable to USANA (GAAP)** | $**(6522)** | $**10607** | $**12535** | $**37576** |
| Net earnings (loss) attributable to noncontrolling interest | (140) |  | 537 |  |
| **Net earnings (loss)** | $**(6662)** | $**10607** | $**13072** | $**37576** |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | $8456 | $8001 | $24278 | $28346 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest (income) expense | (529) | (3093) | (1201) | (8429) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5112 | 5559 | 16050 | 16345 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets - Hiya | 4455 |  | 13366 |  |
| **Earnings before interest, taxes, depreciation, and amortization (EBITDA)** | $**10832** | $**21074** | $**65565** | $**73838** |
| Add EBITDA adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash share-based compensation | 3576 | 3542 | 10078 | 10945 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction, integration and transition costs - Hiya | 179 |  | 871 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory step-up - Hiya |  |  | 1126 |  |
| Consolidated adjusted EBITDA | 14587 | 24616 | 77640 | 84783 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Adjusted EBITDA attributable to noncontrolling interest | (804) |  | (3604) |  |
| **Adjusted EBITDA attributable to USANA** | $**13783** | $**24616** | $**74036** | $**84783** |

---

------

**Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (non-GAAP)**

**(in thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Nine months ended** | **Nine months ended** |
| | **September 27, 2025** | **September 28, 2024** | **September 27, 2025** | **September 28, 2024** |
| Net earnings (loss) attributable to USANA (GAAP) | $(6522) | $10607 | $12535 | $37576 |
| **Earnings (loss) per common share - Diluted (GAAP)** | $**(0.36)** | $**0.56** | $**0.67** | $**1.96** |
| Weighted Average common shares outstanding - Diluted | 18293 | 19083 | 18671 | 19181 |
| Adjustment to net earnings (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction, integration and transition costs - Hiya | $179 | $— | $871 | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory step-up - Hiya |  |  | 1126 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets - Hiya | 4455 |  | 13366 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to net earnings (loss) attributable to noncontrolling interest | (941) |  | (3066) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax effect of adjustments to net earnings (loss) |  |  | (4) |  |
| Adjusted net earnings (loss) attributable to USANA | $(2829) | $10607 | $24828 | $37576 |
| **Adjusted earnings (loss) per common share - Diluted** | $**(0.15)** | $**0.56** | $**1.33** | $**1.96** |
| Weighted average common shares outstanding - Diluted | 18293 | 19083 | 18671 | 19181 |

---

------

**Management Commentary Document and Conference Call**

For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Thursday, October 23, 2025 at 11:00 AM Eastern Time. **Investors may listen to the call by accessing USANA's website at http://ir.usana.com**. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

**Safe Harbor** 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as "expect," "enhance," "drive," "anticipate," "intend," "improve," "promote," "should," "believe," "continue," "plan," "goal," "opportunity," "estimate," "predict," "may," "will," "could," and "would," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding Hiya's growth in 2025 and continued growth in the future; statements about the Company's long-term growth; and the statements under the sub-heading "Fiscal Year 2025 Outlook." Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or

------

among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with early stage operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that the Hiya acquisition disrupts each company's current plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability of to retain key personnel of Hiya; the ability to realize the benefits of the acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya's business with USANA's business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

**About USANA**

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy,

------

and India. More information on USANA can be found at **www.usana.com.** USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company with a variety of clean-label products. More information on Hiya can be found at **www.hiyahealth.com.**

Investor contact: Andrew Masuda

Investor Relations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(801) 954-7201

investor.relations@usanainc.com

Media contact: Sarah Searle

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(801) 954-7626

media@usanainc.com

------

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(in thousands, except per share data)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** |
| Net sales | $213670 | $200221 |
| Cost of sales | 48815 | 39257 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 164855 | 160964 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Brand Partner incentives | 77684 | 84068 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 85947 | 61295 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 163631 | 145363 |
| Earnings from operations | 1224 | 15601 |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 578 | 3142 |
| &nbsp;&nbsp;&nbsp;Interest expense | (49) | (49) |
| &nbsp;&nbsp;&nbsp;Other, net | 41 | (86) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | 570 | 3007 |
| Earnings before income taxes | 1794 | 18608 |
| Income taxes | 8456 | 8001 |
| &nbsp;&nbsp;Net (loss) earnings | (6662) | 10607 |
| Less: Net (loss) earnings attributable to redeemable noncontrolling interest | (140) |  |
| &nbsp;&nbsp;Net (loss) earnings attributable to USANA | $(6522) | $10607 |
| (Loss) earnings per common share attributable to USANA |  |  |
| &nbsp;&nbsp;Basic | $(0.36) | $0.56 |
| &nbsp;&nbsp;Diluted | $(0.36) | $0.56 |
| Weighted average common shares outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 18293 | 19078 |
| &nbsp;&nbsp;&nbsp;Diluted | 18293 | 19083 |

---

------

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **As of<br>September 27,<br>2025** | **As of<br>December 28, <br>2024** |
| **ASSETS** | | |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $145349 | $181768 |
| &nbsp;&nbsp;&nbsp;Inventories | 90781 | 69735 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 27935 | 27684 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current assets** | 264065 | 279187 |
| Property and equipment, net | 96212 | 94565 |
| Goodwill | 144288 | 144168 |
| Intangible assets, net | 138159 | 151823 |
| Deferred tax assets | 24157 | 19644 |
| Other assets\* | 59710 | 58806 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $726591 | $748193 |
| **LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $17095 | $11984 |
| &nbsp;&nbsp;&nbsp;Line of credit |  | 23000 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 101569 | 104641 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current liabilities** | 118664 | 139625 |
| Deferred tax liabilities | 4467 | 4073 |
| Other long-term liabilities | 21907 | 18163 |
| Redeemable noncontrolling interest | 53479 | 54223 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity attributable to USANA | 528074 | 532109 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities, redeemable noncontrolling interest, and stockholders' equity** | $726591 | $748193 |

---

\*Includes noncurrent inventories of $2,802 and $2,688 as of 27-Sep-25 and 28-Dec-24, respectively. Total inventories were $93,583 and $72,423 as of 27-Sep-25 and 28-Dec-24, respectively.

------

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**SALES BY REGION**

**(in thousands)**

**(unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | | | | |
| | **September 27,<br>2025** | **September 27,<br>2025** | **September 28,<br>2024** | **September 28,<br>2024** |<br>**Change from prior<br>year** |<br>**Percent change** |<br>**Currency impact on<br>sales** |<br>**Percent change<br>excluding currency<br>impact** |
| Direct Selling: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Asia Pacific |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Greater China | $92571 | 43.3% | $102261 | 51.1% | $(9690) | (9.5%) | $504 | (10.0%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Southeast Asia Pacific | 29178 | 13.7% | 37267 | 18.6% | (8089) | (21.7%) | 393 | (22.8%) |
| &nbsp;&nbsp;&nbsp;&nbsp;North Asia | 17690 | 8.3% | 20541 | 10.2% | (2851) | (13.9%) | (403) | (11.9%) |
| &nbsp;&nbsp;Asia Pacific total | 139439 | 65.3% | 160069 | 79.9% | (20630) | (12.9%) | 494 | (13.2%) |
| &nbsp;&nbsp;Americas and Europe | 36386 | 17.0% | 38398 | 19.2% | (2012) | (5.2%) | 72 | (5.4%) |
| Direct Selling total | 175825 | 82.3% | 198467 | 99.1% | (22642) | (11.4%) | 566 | (11.7%) |
| Hiya | 30846 | 14.4% |  | —% | 30846 | N/A |  | N/A |
| Other | 6999 | 3.3% | 1754 | 0.9% | 5245 | 299.0% |  | 299.0% |
| Consolidated total | $213670 | 100.0% | $200221 | 100.0% | $13449 | 6.7% | $566 | 6.4% |

---

------

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**DIRECT SELLING ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Direct Selling Active Brand Partners by Region**<sup>(1)</sup> | **Direct Selling Active Brand Partners by Region**<sup>(1)</sup> | **Direct Selling Active Brand Partners by Region**<sup>(1)</sup> | **Direct Selling Active Brand Partners by Region**<sup>(1)</sup> | **Direct Selling Active Brand Partners by Region**<sup>(1)</sup> |
| **(unaudited)** | **(unaudited)** | **(unaudited)** | **(unaudited)** | **(unaudited)** |
| | **As of <br>September 27, 2025** | **As of <br>September 27, 2025** | **As of <br>September 28, 2024** | **As of <br>September 28, 2024** |
| Asia Pacific |  |  |  |  |
| &nbsp;&nbsp;Greater China | 61000 | 36.3% | 65000 | 34.6% |
| &nbsp;&nbsp;Southeast Asia Pacific | 43000 | 25.6% | 52000 | 27.6% |
| &nbsp;&nbsp;North Asia | 27000 | 16.1% | 28000 | 14.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific Total | 131000 | 78.0% | 145000 | 77.1% |
| Americas and Europe | 37000 | 22.0% | 43000 | 22.9% |
|  | 168000 | 100.0% | 188000 | 100.0% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Direct Selling Active Preferred Customers by Region**<sup>(2)</sup> | **Direct Selling Active Preferred Customers by Region**<sup>(2)</sup> | **Direct Selling Active Preferred Customers by Region**<sup>(2)</sup> | **Direct Selling Active Preferred Customers by Region**<sup>(2)</sup> | **Direct Selling Active Preferred Customers by Region**<sup>(2)</sup> |
| **(unaudited)** | **(unaudited)** | **(unaudited)** | **(unaudited)** | **(unaudited)** |
| | **As of <br>September 27, 2025** | **As of <br>September 27, 2025** | **As of <br>September 28, 2024** | **As of <br>September 28, 2024** |
| Asia Pacific |  |  |  |  |
| &nbsp;&nbsp;Greater China | 149000 | 67.7% | 178000 | 67.4% |
| &nbsp;&nbsp;Southeast Asia Pacific | 18000 | 8.2% | 24000 | 9.1% |
| &nbsp;&nbsp;North Asia | 10000 | 4.6% | 13000 | 4.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific Total | 177000 | 80.5% | 215000 | 81.4% |
| Americas and Europe | 43000 | 19.5% | 49000 | 18.6% |
|  | 220000 | 100.0% | 264000 | 100.0% |

---

**______________________________**

<sup>(1)</sup> Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale.

<sup>(2)</sup> Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

------

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**OPERATING RESULTS AS A PERCENTAGE OF NET SALES**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** |
| | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** |
| | **Direct selling & Other** | **Hiya direct-to-consumer** | **Consolidated** | **Direct selling & Other** | **Hiya direct-to-consumer** | **Consolidated** |
| Net sales | 100.0% | 100.0% | **100.0%** | 100.0% | N/A | **100.0%** |
| Cost of sales | 20.7% | 35.6% | **22.8%** | 19.6% | N/A | **19.6%** |
| &nbsp;&nbsp;&nbsp;Gross profit | 79.3% | 64.4% | **77.2%** | 80.4% | N/A | **80.4%** |
| Operating expenses: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Brand Partner incentives | 42.5% | —% | **36.4%** | 42.0% | N/A | **42.0%** |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 35.8% | 66.5% | **40.2%** | 30.6% | N/A | **30.6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 78.3% | 66.5% | **76.6%** | 72.6% | N/A | **72.6%** |
| Earnings (loss) from operations | 1.0% | (2.1)% | **0.6%** | 7.8% | N/A | **7.8%** |
| Amortization of acquired intangible assets | 0.2% | 14.5% | **2.2%** | 0.1% | N/A | **0.1%** |
|  | **Nine months ended** | **Nine months ended** | **Nine months ended** | **Nine months ended** | **Nine months ended** | **Nine months ended** |
|  | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** |
|  | **Direct selling & Other** | **Hiya direct-to-consumer** | **Consolidated** | **Direct selling & Other** | **Hiya direct-to-consumer** | **Consolidated** |
| Net sales | 100.0% | 100.0% | **100.0%** | 100.0% | N/A | **100.0%** |
| Cost of sales | 19.1% | 36.7% | **21.7%** | 19.1% | N/A | **19.1%** |
| &nbsp;&nbsp;&nbsp;Gross profit | 80.9% | 63.3% | **78.3%** | 80.9% | N/A | **80.9%** |
| Operating expenses: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Brand Partner incentives | 42.7% | —% | **36.4%** | 42.2% | N/A | **42.2%** |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 33.0% | 60.8% | **37.1%** | 29.6% | N/A | **29.6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 75.7% | 60.8% | **73.5%** | 71.8% | N/A | **71.8%** |
| Earnings from operations | 5.2% | 2.5% | **4.8%** | 9.1% | N/A | **9.1%** |
| Amortization of acquired intangible assets | 0.2% | 13.1% | **2.0%** | 0.2% | N/A | **0.2%** |

---

## Exhibit 99.2

![usanacorplogoresizeda.jpg](usanacorplogoresizeda.jpg)

**USANA Health Sciences, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; October 22, 2025**

***Q3 2025 Management Commentary***

**Key Financial Results**

---

| | | | |
|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | |
| | **September 27,<br>2025** | **September 28,<br>2024** |<br>**Year-Over-Year** |
| Net Sales | $214 | $200 | +7% |
| Net (Loss) Earnings\* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$-6.5 | $10.6 | N/A |
| Diluted EPS | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$(0.36) | $0.56 | N/A |
| Adjusted Diluted EPS<sup>(1)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$(0.15) | $0.56 | N/A |
| Adjusted EBITDA<sup>(2)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$13.8 | $24.6 | -44% |
| Direct Selling Active Customers | 388000 | 452000 | -14% |
| Hiya Active Monthly Subscribers | 193400 | N/A | N/A |

---

*\*Pretax earnings for Q3 2025 totaled $1.8 million with income tax expense of $8.5 million. The adjustment to income taxes during the period, as a result of updating the annual effective tax rate, is about $7.6 million greater than what would have been expected using the previously guided 45% tax rate.*

*Figures in millions, except per share, Active Customer and Active Monthly Subscriber data.*

*Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.*

**Overview**

We provided third quarter results in line with the preliminary results we announced on October 9th. We rolled out our enhanced Brand Partner compensation plan during the third quarter. Since this launch, our commercial team has been actively training, educating and supporting Brand Partners across our global markets to help them leverage the new plan. Overall feedback from our Brand Partners has been positive and, although still early, we are encouraged by a pickup in sales activity and leader productivity in recent weeks. We plan to offer short-term incentives during the fourth quarter as part of our efforts to maintain this momentum.

During the third quarter, we held a successful Global Convention in Salt Lake City where we launched several new and upgraded products, recognized our top sales leaders and held

------

numerous training sessions for our Brand Partners. Our product teams will be working to roll out these recently launched products to all of our markets globally over the next several quarters. Additionally, we will continue to develop our marketing and training materials around these products to align with USANA's commitment to quality, excellence, and innovation.

Our commercial team will remain actively engaged in prioritizing in-person meetings with our Brand Partners in the fourth quarter and into next year, with a focus on training and education, to ensure these recent product launches and compensation plan enhancements are successful and fully leveraged by our global active Brand Partners. Additionally, our team will continue to strengthen content creation at the regional and local levels to enhance our global Brand Partners' ability to share, attract, and recruit new Brand Partners and customers.

Hiya, our direct-to-consumer (DTC) business, has delivered 26% year-to-date sales growth, and made significant progress on several integration initiatives during the quarter, including the transition to a new logistics partner, which is anticipated to drive operational efficiency. We are also leveraging USANA's manufacturing expertise to support Hiya and will begin bringing their products in-house over the next several months. We continue to expect Hiya to generate double-digit sales growth for 2025 and remain confident in their long-term growth.

Rise Bar, which was acquired in 2022, reported another quarter of strong top-line growth, with net sales more than tripling compared to the prior-year quarter, driven by solid order activity with key retail partners. The Rise Bar team remains focused on expanding its product offering and expanding into the wholesale and retail channels. While still relatively small, we are encouraged by the recent momentum in this healthy-foods business and believe there is meaningful growth opportunity in this space over the next several years.

**Balance Sheet**

We ended the third quarter with $145 million in cash and cash equivalents and no debt. As of September 27, 2025,we had approximately $34 million remaining under the current share repurchase authorization

------

Inventories increased to $94 million as of September 27, 2025, or 29% higher compared to the year-end balance in fiscal 2024. The increase in inventory was driven, in great part, by new product introductions and investments necessary to support our growth strategies and bring manufacturing in-house for our venture companies: Hiya and Rise Bar. Additionally, activities to mitigate tariff exposure, including sourcing strategies, as well as softer year-over-year net sales also contributed to the increase in inventory. We believe our in-house manufacturing capabilities provide us with better margins, improved control of inventory levels, and help to mitigate supply chain risks while providing a meaningful contribution to delivering the highest quality nutritional products.

**Quarterly Income Statement Discussion**

As part of the reorganization of our commercial team in our direct selling business that took place over the last year, there has been a shift in where we record certain expenses. For example, certain activities and individuals were repurposed into new areas of focus and, as a result, those expenses that had historically been captured as a component of cost of sales are now included in selling, general and administrative expense. This change totaled an estimated $1.7 million shift from COGS to SG&A during the third quarter.

<u>Gross margin decreased 320 basis points from the prior year to 77.2% of net sales.</u> The decrease is largely attributed to an approximate 210 basis point unfavorable impact on consolidated results from the inclusion of Hiya, which carries lower gross margins relative to the direct selling business. Gross margin in the direct selling and other business declined 110 basis points from the prior year to 79.3% of segment net sales. These declines were partially offset by the previously mentioned change in cost attribution related to the reorganization of the commercial team and modest price increases.

<u>Brand Partner Incentives decreased 560 basis points from the prior year to 36.4% of net sales on a consolidated basis.</u> The decrease is largely attributable to an approximate 610 basis point impact on consolidated results from the inclusion of Hiya, which does not pay out Brand Partner Incentives. For the direct selling business, Brand Partner Incentives increased 50 basis points from the prior year to 42.5% of segment net sales, which was driven primarily by a change in

------

market sales mix as well as higher accruals for incentives related to the roll out of our enhanced Brand Partner compensation plan.

<u>Selling, General and Administrative expenses increased 960 basis points from the prior year to 40.2% as a percentage of net sales.</u> SG&A expenses for the direct selling business increased 520 basis points from the prior year to 35.8% of segment net sales. The increase is primarily attributable to a $3.5 million increase in spending related to our Global Convention and the loss of leverage on lower year-over-year net sales. The change in the activities and organization of the commercial team also contributed to the increase. The combined SG&A increase also reflects an approximate 440 basis point unfavorable impact on consolidated results from the inclusion of Hiya, which operates with higher relative SG&A compared to the direct selling business. A notable component of our higher consolidated SG&A is the amortization of intangible assets attributable to our acquisition of Hiya. Additionally, Hiya's third quarter SG&A expense reflects typical seasonality with higher relative investment in marketing spend directed toward customer acquisition.

<u>The year-to-date effective tax rate increased to 65.0% from the 43.0% reported in the comparable period of 2024.</u> The higher effective tax rate was driven by lower-than-expected earnings coupled with the concentration of operating and administrative expenses in the United States, resulting in a meaningful increase in the annualized effective income tax rate in the third quarter. Pretax earnings for Q3 2025 totaled $1.8 million with income tax expense of $8.5 million, resulting in a 471% income tax rate for the period. The adjustment to income taxes during the period were approximately $7.6 million greater than what was expected using the previously guided 45% tax rate.

**Q3 2025 Direct Selling Regional Results:**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** | **Asia Pacific Region** |
| | | **Year-Over-Year** | **Year-Over-Year (Constant Currency)** | **Sequentially** |
| **Net Sales** | $140 million | -13% | -13% | -15% |
| **Active Customers** | 308000 | -14% | N/A | -8% |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** | **Asia Pacific Sub-Regions** |
| | | | **Year-Over-Year** | **Year-Over-Year (Constant Currency)** | **Sequentially** |
| **Greater China** | **Net Sales** | $93 million | -9% | No meaningful FX impact | -18% |
| **Greater China** | **Active** | 210000 | -14% | N/A | -9% |
| **Greater China** | **Customers** | 210000 | -14% | N/A | -9% |
| **North Asia** | **Net Sales** | $18 million | -14% | -12% | +3% |
| **North Asia** | **Active** | 37000 | -10% | N/A | —% |
| **North Asia** | **Customers** | 37000 | -10% | N/A | —% |
| **Southeast Asia Pacific** | **Net Sales** | $29 million | -22% | -23% | -11% |
| **Southeast Asia Pacific** | **Active** | 61000 | -20% | N/A | -10% |
| **Southeast Asia Pacific** | **Customers** | 61000 | -20% | N/A | -10% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** | **Americas and Europe Region** |
| | | **Year-Over-Year** | **Year-Over-Year (Constant Currency)** | **Sequentially** |
| **Net Sales\*** | $43 million | +8% | +8% | +12% |
| **Active Customers** | 80000 | -13% | N/A | -2% |
| *\*Includes $7 million of 'Other'* | *\*Includes $7 million of 'Other'* |  |  |  |

---

Net sales results and active customer counts across each of our key sub-regions reflected lower than anticipated Brand Partner productivity during the rollout of our enhanced Brand Partner compensation plan. We anticipated a slowdown during this transition, however, it was more pronounced than expected.

**Q3 2025 Hiya Direct to Consumer Results:**

---

| | |
|:---|:---|
| **Hiya** | **Hiya** |
| **Net Sales** | $31 million |
| **Active Monthly Subscribers** | 193400 |

---

Third quarter results were softer than anticipated due to lower customer acquisition rates in a quarter that is typically seasonally strong. As a result, net sales and Active Monthly Subscribers declined 7% and 3% sequentially, respectively. Looking forward, Hiya began the fourth quarter

------

with a lower base of active customers in a quarter that is typically lighter compared to the first and third quarters. As such, we anticipate net sales at similar levels to the third quarter. For the full year 2025, Hiya is projected to deliver 16% sales growth. We remain confident in Hiya's long-term strategies to increase its market share in the children's health and wellness market by further growing and expanding its product offering, entering new distribution channels, and expanding its geographic footprint in international markets. We also expect improved operating margins as a result of USANA/Hiya synergies.

**Fiscal Year 2025 Outlook**

The Company is updating its outlook for fiscal year 2025, as follows:

---

| | | |
|:---|:---|:---|
| **Fiscal Year 2025 Outlook** | **Fiscal Year 2025 Outlook** | **Fiscal Year 2025 Outlook** |
| | **Updated Estimate** | **Previous Range** |
| **Consolidated Net Sales** | $920 million | $920 million to $1.0 billion |
| **Net Earnings** | $15 million | $29 million to $41 million |
| **Diluted EPS** | $0.78 | $1.50 to $2.20 |
| **Adjusted Diluted EPS**<sup>(1)</sup> | $1.73 | $2.35 to $3.00 |
| **Adjusted EBITDA**<sup>(2)</sup> | $98 million | $107 million to $123 million |

---

*Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya*

Our outlook for the year reflects:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales from the direct selling business of approximately $788 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales from Hiya of approximately $132 million, reflecting year-over-year growth of 16%; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Fiscal 2025 is a 53-week year and includes one additional week of sales compared to fiscal 2024. Prior to 2025, the last 53-week year was in fiscal 2020.

We are revising our fiscal 2025 outlook, which reflects modest sequential improvement in both our direct sales and DTC businesses, albeit from a lower-than-anticipated customer base as a result of third quarter performance. Over the next several quarters we will continue to focus on top-line growth while simultaneously emphasizing profitability. We have initiated and are executing a comprehensive process to align all costs throughout the business globally. This process will both support business strategy and make progress in aligning organizational costs with sales performance. As a result of this realignment and rightsizing process, we expect to

------

incur an estimated one-time charge of $4.7 million in the fourth quarter, which is reflected in our updated outlook. We will provide an update on this process, including the actual charge, when we report our fourth quarter and full-year results early next year.

In closing, we remain confident that our comprehensive commercial team strategy will position USANA to drive growth in our direct selling business and deliver long-term value for our customers and Brand Partners. Additionally, we remain confident in the growth opportunity that Hiya provides as it expands its presence in the children's health and wellness market. Furthermore, we are optimistic about the potential of Rise Bar, which, though currently operating from a small base, is poised for meaningful future growth as they expand product offerings in the retail channel. Together, these elements reinforce our positive outlook for the future and our commitment to create lasting value across our portfolio.

**Jim Brown**

President and CEO

**Douglas Hekking**

CFO

------

_________________________

(1) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted Earnings Per Share. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

(2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

**Non-GAAP Financial Measures** 

This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, and transaction-related expenses and integration costs for the Hiya acquisition. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.

------

Adjusted diluted earnings per share (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, and integration costs related to the Hiya acquisition.

Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted earnings per share (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP") and investors should not directly compare with or infer relationship from any of the Company's operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted earnings per share. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.

------

**Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP)**

**(in thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Nine months ended** | **Nine months ended** |
| | **September 27, 2025** | **September 28, 2024** | **September 27, 2025** | **September 28, 2024** |
| **Net earnings (loss) attributable to USANA (GAAP)** | $**(6522)** | $**10607** | $**12535** | $**37576** |
| Net earnings (loss) attributable to noncontrolling interest | (140) |  | 537 |  |
| **Net earnings (loss)** | $**(6662)** | $**10607** | $**13072** | $**37576** |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | $8456 | $8001 | $24278 | $28346 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest (income) expense | (529) | (3093) | (1201) | (8429) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5112 | 5559 | 16050 | 16345 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets - Hiya | 4455 |  | 13366 |  |
| **Earnings before interest, taxes, depreciation, and amortization (EBITDA)** | $**10832** | $**21074** | $**65565** | $**73838** |
| Add EBITDA adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash share-based compensation | 3576 | 3542 | 10078 | 10945 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction, integration and transition costs - Hiya | 179 |  | 871 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory step-up - Hiya |  |  | 1126 |  |
| Consolidated adjusted EBITDA | 14587 | 24616 | 77640 | 84783 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Adjusted EBITDA attributable to noncontrolling interest | (804) |  | (3604) |  |
| **Adjusted EBITDA attributable to USANA** | $**13783** | $**24616** | $**74036** | $**84783** |

---

------

**Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted (Loss) Diluted Earnings Per Share (non-GAAP)**

**(in thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Nine months ended** | **Nine months ended** |
| | **September 27, 2025** | **September 28, 2024** | **September 27, 2025** | **September 28, 2024** |
| Net earnings (loss) attributable to USANA (GAAP) | $(6522) | $10607 | $12535 | $37576 |
| **Earnings (loss) per common share - Diluted (GAAP)** | $**(0.36)** | $**0.56** | $**0.67** | $**1.96** |
| Weighted Average common shares outstanding - Diluted | 18293 | 19083 | 18671 | 19181 |
| Adjustment to net earnings (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction, integration and transition costs - Hiya | $179 | $— | $871 | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory step-up - Hiya |  |  | 1126 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets - Hiya | 4455 |  | 13366 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to net earnings (loss) attributable to noncontrolling interest | (941) |  | (3066) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax effect of adjustments to net earnings (loss) |  |  | (4) |  |
| Adjusted net earnings (loss) attributable to USANA | $(2829) | $10607 | $24828 | $37576 |
| **Adjusted earnings (loss) per common share - Diluted** | $**(0.15)** | $**0.56** | $**1.33** | $**1.96** |
| Weighted average common shares outstanding - Diluted | 18293 | 19083 | 18671 | 19181 |

---

------

**Operating Results as a Percentage of Net Sales**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** | **Quarter Ended** |
| | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** |
| | **Direct selling & Other** | **Hiya direct-to-consumer** | **Consolidated** | **Direct selling & Other** | **Hiya direct-to-consumer** | **Consolidated** |
| Net sales | 100.0% | 100.0% | **100.0%** | 100.0% | N/A | **100.0%** |
| Cost of sales | 20.7% | 35.6% | **22.8%** | 19.6% | N/A | **19.6%** |
| &nbsp;&nbsp;&nbsp;Gross profit | 79.3% | 64.4% | **77.2%** | 80.4% | N/A | **80.4%** |
| Operating expenses: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Brand Partner incentives | 42.5% | —% | **36.4%** | 42.0% | N/A | **42.0%** |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 35.8% | 66.5% | **40.2%** | 30.6% | N/A | **30.6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 78.3% | 66.5% | **76.6%** | 72.6% | N/A | **72.6%** |
| Earnings (loss) from operations | 1.0% | (2.1)% | **0.6%** | 7.8% | N/A | **7.8%** |
| Amortization of acquired intangible assets | 0.2% | 14.5% | **2.2%** | 0.1% | N/A | **0.1%** |
|  | **Nine months ended** | **Nine months ended** | **Nine months ended** | **Nine months ended** | **Nine months ended** | **Nine months ended** |
|  | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** |
|  | **Direct selling & Other** | **Hiya direct-to-consumer** | **Consolidated** | **Direct selling & Other** | **Hiya direct-to-consumer** | **Consolidated** |
| Net sales | 100.0% | 100.0% | **100.0%** | 100.0% | N/A | **100.0%** |
| Cost of sales | 19.1% | 36.7% | **21.7%** | 19.1% | N/A | **19.1%** |
| &nbsp;&nbsp;&nbsp;Gross profit | 80.9% | 63.3% | **78.3%** | 80.9% | N/A | **80.9%** |
| Operating expenses: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Brand Partner incentives | 42.7% | —% | **36.4%** | 42.2% | N/A | **42.2%** |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 33.0% | 60.8% | **37.1%** | 29.6% | N/A | **29.6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 75.7% | 60.8% | **73.5%** | 71.8% | N/A | **71.8%** |
| Earnings from operations | 5.2% | 2.5% | **4.8%** | 9.1% | N/A | **9.1%** |
| Amortization of acquired intangible assets | 0.2% | 13.1% | **2.0%** | 0.2% | N/A | **0.2%** |

---

------

**Safe Harbor** 

This Management Commentary contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as "expect," "enhance," "drive," "anticipate," "intend," "improve," "promote," "should," "believe," "continue," "plan," "goal," "opportunity," "estimate," "predict," "may," "will," "could," and "would," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding Hiya's growth in 2025 and continued growth in the future; statements about the Company's long-term growth; and the statements under the sub-heading "Fiscal Year 2025 Outlook." Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with early stage operations in India and future international expansion

------

and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that the Hiya acquisition disrupts each company's current plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability of to retain key personnel of Hiya; the ability to realize the benefits of the acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya's business with USANA's business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this Management Commentary set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

**About USANA**

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at **www.usana.com.** USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company with a variety of clean-label products. More information on Hiya can be found at **www.hiyahealth.com.**

Investor contact: Andrew Masuda

Investor Relations

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(801) 954-7201

investor.relations@usanainc.com

Media contact: Sarah Searle

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(801) 954-7626

media@usanainc.com

<br>